- Trial phase
- Phase 2a (completed)
- Time to market
- Unknown, Phase 2a completed, Phase 2b not yet initiated; a partnership-dependent path with no announced timeline
- Why 2/10
- No hard dated catalyst exists for RXC007 in the next ~12 months, Phase 2a has already reported, no Phase 2b start date has been set, and the drug is being positioned for partnering rather than internal advancement by the combined Fibrx entity.
RXC007 has no scheduled binary catalyst; the key event to watch is the Skye-Redx merger closing (expected Q4 2026) and whether Fibrx announces a partnering deal for RXC007 afterwards. Any partnership terms (upfront, milestones) could serve as a partial valuation floor for this asset.
Price Chart
Executive Summary
RXC007 (zelasudil) is a selective ROCK2 inhibitor that has completed a Phase 2a signal-searching study in idiopathic pulmonary fibrosis (IPF), showing a well-tolerated safety profile and encouraging early efficacy signals including a numerical reduction in FVC decline. Originally developed by private UK biotech Redx Pharma, the asset is being acquired by Skye Bioscience (SKYE) via a reverse-merger announced August 14, 2026, that will form a new Nasdaq-listed entity called Fibrx Therapeutics. However, RXC007 is not the combined company's lead asset, that distinction belongs to RXC008 (for fibrostenotic Crohn's disease). RXC007 is explicitly positioned for out-licensing/partnering, and no Phase 2b trial start date or specific development timeline has been announced. The drug currently lacks a near-term binary catalyst, and its value to SKYE/Fibrx shareholders depends on securing a partnership deal.
How It Works
RXC007 (zelasudil) is a small-molecule pill that selectively inhibits ROCK2, an enzyme involved in promoting fibrosis (scar tissue formation). By blocking ROCK2, the drug aims to reduce the excessive scarring that damages organs in diseases like idiopathic pulmonary fibrosis (IPF), a progressive lung disease where the lungs become stiff and scarred.
Trial Status
Phase 2a signal-searching study in IPF completed H1 2025 with results presented at ERS September 2025 (NCT05570058). The trial showed the drug was well-tolerated with early anti-fibrotic activity signals. A Phase 2b has been discussed as a future step but not initiated or publicly dated. RXC007 is being positioned by Fibrx Therapeutics for partnering rather than internal advancement.
The Two-Sided Case
Upcoming Catalysts
- Skye-Redx merger closing expected Q4 2026 (corporate event, not drug-specific)
- Potential partnership/out-licensing announcement for RXC007, no timeline
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Skye Bioscience, Inc. PREM14A SKYE ·Originating report